UNBELIEVABLE: Eli lilly - Caught on Camera

Adults Newly Facing Leukemia Treatment Gain Another Pill Option as FDA Clears Jaypirca for Untreated CLL

FDA approved Lilly's Jaypirca as a first treatment for adults with CLL or SLL without 17p deletion. Here are the trial results, side effects, and costs.

Medical Daily · 13h ago

Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Counted

A Lilly-funded modeling analysis tied Foundayo to a 57% lower predicted 10-year diabetes risk. No actual diabetes cases were counted in the study.

Medical Daily · Oct 3

Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in Adults with Diabetes and BMI of 35 or Higher

Full Lancet results for Lilly's retatrutide show 23.4% weight loss in adults with type 2 diabetes and a BMI of 35 or higher. The drug remains unapproved.

Medical Daily · Oct 2

Eli Lilly vs. Novo: The Hidden Battle Behind the Weight-Loss Platform Reshaping Industries

GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.

Barchart · Sep 30

3 Emerging Biotech Stocks With Significant Upside Potential

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

MarketBeat · Sep 30

4 Stocks That Could Split Next—and Why Investors Are Watching

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

MarketBeat · Sep 30

Breakthrough weight-loss drug helps diabetes patients lose a quarter of their body weight

Eli Lilly’s retatrutide works by imitating three separate hormones to manage appetite, blood sugar and metabolism

The Independent UK · Sep 29

‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event

Critics say partnership between Mounjaro maker Eli Lilly and fashion giant suggests thinness is an aspiration

The Guardian - UK · Sep 27

Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.

The Economic Times · Sep 26

Florida Sues Insulin Makers and Drug Middlemen, Alleging Pricing Deals Raised Costs for Residents Who Rely on Insulin

Florida's attorney general alleges insulin makers and PBMs inflated the list prices that many patients pay. What the lawsuit claims and how to cut costs.

Medical Daily · Sep 25